Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group protocol 83-11.
Curran WJ Jr, Cox JD, Azarnia N, Byhardt RW, Shin KH, Emani B, Phillips TL, Selim H, Herskovic A, Mohiuddin M, et al. Curran WJ Jr, et al. Among authors: azarnia n. Cancer. 1991 Aug 1;68(3):509-16. doi: 10.1002/1097-0142(19910801)68:3<509::aid-cncr2820680311>3.0.co;2-7. Cancer. 1991. PMID: 1648432 Clinical Trial.
A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. Cox JD, et al. Among authors: azarnia n. J Clin Oncol. 1990 Sep;8(9):1543-55. doi: 10.1200/JCO.1990.8.9.1543. J Clin Oncol. 1990. PMID: 2167952 Clinical Trial.
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G. Nazha A, et al. Among authors: azarnia n. Blood Cancer J. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7. Blood Cancer J. 2017. PMID: 29238044 Free PMC article. Clinical Trial. No abstract available.
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Valero V, et al. Among authors: azarnia n. J Clin Oncol. 1999 May;17(5):1425-34. doi: 10.1200/JCO.1999.17.5.1425. J Clin Oncol. 1999. PMID: 10334527 Clinical Trial.
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK. Lenz HJ, et al. Among authors: azarnia n. J Clin Oncol. 2006 Oct 20;24(30):4914-21. doi: 10.1200/JCO.2006.06.7595. J Clin Oncol. 2006. PMID: 17050875 Clinical Trial.
33 results